BACKGROUND: It is known that bezafibrate decreases serum alkaline phosphatase (ALP) in patients with hyperlipidemia, and the efficacy of this drug for the treatment of primary biliary cirrhosis has been confirmed. However, there has been little evidence of its efficacy for the treatment of primary sclerosing cholangitis (PSC). METHODS: Bezafibrate (400 mg/day) was orally administered to 7 consecutive patients with PSC, and we analyzed their clinical features and the drug efficacy in terms of the effect on hepatobiliary enzymes, including ALP, gamma-glutamyl transpeptidase (gamma-GTP), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) after 6 months. The latest hepatobiliary enzyme levels were also evaluated. RESULTS: In 3 patients (effective group), the levels of all hepatobiliary enzymes had decreased after 6 months. Mean ALP had decreased to approximately 40% of the baseline in this group. The efficacy of bezafibrate was observed for a long period (range, 8-27 months) in these 3 patients. There seemed to be no definite association between the efficacy of bezafibrate and the clinical features in the short term. CONCLUSIONS: This study showed that bezafibrate could lower the levels of hepatobiliary enzymes in about half of a cohort of patients with PSC.
BACKGROUND: It is known that bezafibrate decreases serum alkaline phosphatase (ALP) in patients with hyperlipidemia, and the efficacy of this drug for the treatment of primary biliary cirrhosis has been confirmed. However, there has been little evidence of its efficacy for the treatment of primary sclerosing cholangitis (PSC). METHODS:Bezafibrate (400 mg/day) was orally administered to 7 consecutive patients with PSC, and we analyzed their clinical features and the drug efficacy in terms of the effect on hepatobiliary enzymes, including ALP, gamma-glutamyl transpeptidase (gamma-GTP), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) after 6 months. The latest hepatobiliary enzyme levels were also evaluated. RESULTS: In 3 patients (effective group), the levels of all hepatobiliary enzymes had decreased after 6 months. Mean ALP had decreased to approximately 40% of the baseline in this group. The efficacy of bezafibrate was observed for a long period (range, 8-27 months) in these 3 patients. There seemed to be no definite association between the efficacy of bezafibrate and the clinical features in the short term. CONCLUSIONS: This study showed that bezafibrate could lower the levels of hepatobiliary enzymes in about half of a cohort of patients with PSC.
Authors: Suresh T Chari; Thomas C Smyrk; Michael J Levy; Mark D Topazian; Naoki Takahashi; Lizhi Zhang; Jonathan E Clain; Randall K Pearson; Bret T Petersen; Santhi Swaroop Vege; Michael B Farnell Journal: Clin Gastroenterol Hepatol Date: 2006-07-14 Impact factor: 11.382
Authors: H J van Hoogstraten; F H Wolfhagen; P C van de Meeberg; H Kuiper; G A Nix; M C Becx; A C Hoek; D P van Houte; M C Rijk; J M Salemans; J Scherpenisse; M Schrijver; A M Smit; P Spoelstra; P H Stadhouders; T G Tan; W C Hop; F J ten Kate; G P vanBerge-Henegouwen; S W Schalm; H R van Buuren Journal: J Hepatol Date: 1998-09 Impact factor: 25.083
Authors: Alessio Gerussi; Martina Lucà; Laura Cristoferi; Vincenzo Ronca; Clara Mancuso; Chiara Milani; Daphne D'Amato; Sarah Elizabeth O'Donnell; Marco Carbone; Pietro Invernizzi Journal: Front Med (Lausanne) Date: 2020-04-07